Sumitomo Pharma Co., Ltd.(4506) News

Sumitomo Pharma Selected as Highest Rating A-List Company by CDP for Two Consecutive Years in the Category of Climate Change in the CDP 2025

Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the ASH 2025

Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2026

Presentation Material (Conference on Q2 FY2025 Financial Results)

Summary of Consolidated Financial Results for the Second Quarter (First Half) of the Year Ending March 31, 2026 [IFRS]

(Progress of Disclosure Matters) Confirmation of Gain on Sales of Shares of Subsidiaries in connection with the Company Split of Asian Business

Sumitomo Pharma Announces Variances Between Its Financial Forecasts for the Half-Year Ended September 30, 2025, and Revisions to Financial Forecasts

Sumitomo Pharma, Net Income Forecast for the Fiscal Year Revised Upward by 2.3 times, Highest in Four Terms

Submission of the Application of Manufacturing and Marketing Authorization for iPS Cell-Derived dopaminergic neural progenitor cells in Japan

Sumitomo Pharma, Returning to Profitability This Year

Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2026

Presentation Material (Conference on Q1 FY2025 Financial Results)

(Progress of Disclosure Matters) Completion of Procedures for Company Split of Asian Business and Share Transfer to Marubeni Global Pharma

Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2026 [IFRS]

Notice Concerning Finance Costs

Corporate Governance Report

Matters Concerning Controlling Shareholders, Etc.

Notice of Assignment of Assets for Key Products in the U.S. within Sumitomo Pharma Group

(Progress of disclosure matters) Notice Regarding a Company Split of the Asian Business and Share Transfer with Marubeni Global Pharma Corporation

Presentation Material Conference on FY2024 Financial Results and Reboot 2027 Reboot for a Strong Sumitomo Pharma